CERo Therapeutics Holdings, Inc. (CERO)

CERO Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	3.38	0.1	0.48	1.1
Cash & Short-Term Investments	3.38	0.1	0.48	1.1
Cash Growth	2740.17%	-79.64%	-56.68%	-
Prepaid Expenses	0.33	0.03	0.23	0.26
Restricted Cash	-	-	41.67	-
Other Current Assets	-	8.44	-	-
Total Current Assets	3.71	8.56	42.37	1.36
Long-Term Deferred Tax Assets	-	-	-	0.02
Other Long-Term Assets	-	-	-	178.7
Total Assets	6.49	8.56	42.37	180.08
Accounts Payable	6.67	3.54	1.65	0.01
Accrued Expenses	1.69	0.06	0	0.08
Short-Term Debt	0.1	1.56	0.65	-
Current Income Taxes Payable	-	0.02	0.6	-
Other Current Liabilities	0.03	-	27.84	-
Total Current Liabilities	9.42	5.17	30.75	0.1
Other Long-Term Liabilities	-	17.59	22.62	187.65
Total Liabilities	10.19	22.76	53.37	187.75
Common Stock	0.01	0	0	0
Retained Earnings	-71.59	-14.2	-11	-7.67
Shareholders' Equity	-3.7	-14.2	-11	-7.67
Total Liabilities & Equity	6.49	8.56	42.37	180.08
Total Debt	1.8	1.56	0.65	-
Net Cash (Debt)	1.58	-1.46	-0.17	1.1
Net Cash Per Share	-	-0.22	-0.01	0.11
Filing Date Shares Outstanding	-	14.72	6.77	22.98
Total Common Shares Outstanding	-	6.25	6.77	22.98
Working Capital	-5.71	3.39	11.62	1.26
Book Value Per Share	-	-2.27	-1.62	-0.33
Tangible Book Value	-7.29	-14.2	-11	-7.67
Tangible Book Value Per Share	-	-2.27	-1.62	-0.33

Source: S&P Capital IQ. Standard template. Financial Sources.